Finished
Panitumumab IRDye800 Optical Imaging Study
NCT02415881 · Eben Rosenthal · Updated 24 Sept 2021
- What is being tested
- Panitumumab IRDye 800; da Vinci Firefly; IMAGE1 + ICG Hopkins telescope and/or VITOM
- For
- Head and Neck Cancer
- Kind of study
- Tests a treatment or device on volunteers. Phase 1.
- Who can join
- Ages 19 years and older. About 64 people. The full rules are on the registry page.
- Where
- United States (2 sites)
- When
- Starts or started Aug 2016, ends 21 Sept 2021. Registered 14 April 2015.
- Results
- None posted yet.
In the researchers' words
Phase I trial to evaluate the safety of escalating dose levels of conjugated panitumumab-IRDye800 in subjects with head and neck squamous cell carcinoma (HNSCC) that undergo surgery with curative intent.
Sites
- University of Alabama at Birmingham Cancer CenterBirmingham, Alabama, United States
- Stanford University, School of MedicineStanford, California, United States